The Drug Is Used To Improve Glycemic Control And Lower The Risk Of Cardiovascular Death In Adults With Type 2 Diabetes. Zydus Lifesciences Ltd Has Received Final Fda Approval To Market Empagliflozin And Metformin Hydrochloride Tablets In 5 Mg/500 Mg, 5 Mg/1000 Mg, 12.5 Mg/500 Mg, And 12.5 Mg/1000 Mg Strengths (Us Rld: Synjardy). Empagliflozin And Metformin Hydrochloride Tablets Are Used With Proper Diet And Exercise To Improve Glycemic Control In Adults With Type 2 Diabetes Mellitus. They Are Also Used To Lower The Risk Of Cardiovascular Death In Patients With Type 2 Diabetes Mellitus And Established Cardiovascular Disease. The Drug Will Be Manufactured At The Group
